Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Amazon Natural (AZNT) -- Ignore unavailable to you. Want to Upgrade?

To: zonkie who wrote (6593)	9/20/1998 6:34:00 PM
From: Janice Shell	Read Replies (1) \| Respond to of 26163

Hey! You left out the BEST ONE!! To: Jeffrey S. Mitchell (4155 ) From: bmart Monday, Sep 7 1998 10:17PM ET Reply # of 6609 Mr. Mitchell, Tonight I met with Dr. Jorge Daaboul of Children's Memorial hospital. Dr. Daaboul is quite enthusiastic about the applications of TON with pediatric diabetic patients. The diabetic population at Children's Memorial is 625 patients. Dr. Daaboul felt that TON had a better taste than Aspartame while containing no phenylanaline. Aspartame is basically phenylanaline. Aspartame is contraindicated for use by pediatric diabetic patients because; * phenylanaline based neurotransmitters are prominent in the brain and CNS of growing children * aspartame has been associated with A.D.D. * decreased attention span Dr. Daaboul also cited TON's applications in celiac disease, where hi-fructose corn sweetners cause gaseousness in patients. Dr. Daabould cited that there are 2-3MM pediatric diabetic patients under the age of 15 in the U.S.. He felt that TON warranted an informal study and will be instructing his nursing staff on using TON as a sweetner and regulating it's use with his patients at Children's Memorial. Success there may lead to a formal study. RB #reply-5689560 Pants on fire.